SavedAdd your journal

Journals / İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi / 2018 / Cilt: 22 - Sayı: 3

RETROSPECTIVE EVALUATION OF OUR PATIENTS WITH DIAGNOSIS NON-HODGKIN LYMPHOMA

NON-HODGKIN LENFOMA TANILI HASTALARIMIZIN RETROSPEKTİF DEĞERLENDİRİLMESİ

Tuğba ÇETİNTEPE
CELAL ACAR
Şerife SOLMAZ
Pages
119–124
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our treatment response and survival rates were also found to be consistent with the literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Demografic features, respond the treatment of 90 Non-Hodgkin lymphoma (NHL) patients observed at depertman of hematology, Bozyaka Traning and Research Hospital in our study.
📊
Key Findings & Data:Material and Method: Data of 90 NHL patients were evaluated retrospectively.
💡
Conclusion & Impact:Our treatment response and survival rates were also found to be consistent with the literature.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: Demografic features, respond the treatment of 90 Non-Hodgkin lymphoma (NHL) patients observed at depertman of hematology, Bozyaka Traning and Research Hospital in our study. Material and Method: Data of 90 NHL patients were evaluated retrospectively. Results: We found that 47 of the patients were women and 43 of the patients and were men and median age were 62. The patients were diagnosed with diffuse large B-cell lymphoma (DBBHL) in 61 patients, marginal zone lymphoma in 15 patients, follicular lymphoma in 6 patients and other lymphoma in 10 patients 18 patients died, and 72 of them lived. We found the median survival 73 months all of the patients. All patients survival (OS) was 75% and disease free- survival rates 68% of 5 year. Conclusion: Demografic features of patients are similar to another studies. Our treatment response and survival rates were also found to be consistent with the literature.

Özet

Giriş: Çalışmamızda Sağlık Bilimleri Üniversitesi Bozyaka Eğitim ve Araştırma Hastanesi Hematoloji Kliniğinde takip edilen 90 Non- Hodgkin lenfoma tanılı (NHL) hastanın demografik verileri, tedavi yanıtları ile sağkalım analizlerinin yapılması amaçlandı. Gereç ve Yöntem: Non- Hodgkin lenfoma tanısı ile izlenen 90 olgunun verileri geriye dönük olarak değerlen- dirildi. Bulgular: Çalışmaya alınan 90 hastadan 47'i kadın,43'i erkekdi. Ortanca yaş 62 olarak saptandı. Hastaların tanılarına bakıldığında 61 hastanın Diffüz büyük B hücreli lenfoma (DBBHL), 15 hastanın marjinal zon lenfoma, 6 hastanın folikuler lenfoma ve 10 hastanın diğer lenfoma tanısı aldığı görüldü. Hastaların 18 tanesi ölmüş, 72 tanesi ise yaşıyor olarak saptandı. Tüm NHL hastalarında ortalama sağkalım süresi 73 ay olarak bulundu. 5 yıllık toplam sağkalım %75, 5 yıllık hastalıksız sağkalım % 68 olarak saptandı. Sonuç: Hastalarımızın demografik özellikleri diğer çalışmalar ile benzerdir. Ayrıca tedavi yanıtlarımız ve sağkalım oranlarımız literature ile uyumlu bulunmuştur.

🔖

Cite This Article

ÇETİNTEPE, T., ACAR, C., SOLMAZ, Ş. (2018). RETROSPECTIVE EVALUATION OF OUR PATIENTS WITH DIAGNOSIS NON-HODGKIN LYMPHOMA. İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi, Cilt: 22 - Sayı: 3, 119–124. https://ajindex.com/articles/195537

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Kenneth F. Lymphomas. In: Beutler E, Lictman M, Kipps T, Seligsohn U, editors. Williams Hematology, 6th ed. New-York: Mc Graw-Hill Companies; 2001: p.1237-63.
  2. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014; 64(4): 252-71.
  3. Müller AM, Ihorst G, Mertelsmann R, Engelhardt M. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol 2005; 84(1): 1-12.
  4. Couderc B, Dujols JP, Mokhtari F, Norkowski JL, Slawinski JC, Schlaifer D. The management of adult aggressive non- Hodgkin's lymphomas. Crit Rev Oncol Hematol 2000; 35(1): 33-48. el-Akkad SM, Amer MH, Lin GS, Sabbah RS, Godwin JT. Pattern of cancer in Saudi Arabs referred to King Faisal Specialist Hospital. Cancer 1986; 58(5): 1172-8.
  5. Isikdogan A, Ayyildiz O, Buyukcelik A, Arslan A, Tiftik N, Buyukbayram H,et al. Non-Hodgkin's lymphoma in southeast Turkey: clinicopathologic features of 490 cases. Ann Hematol 2004; 83(5): 265-9.
  6. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011; 117(19): 5019-32
  7. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61(2): 134. Intragumtornchai T, Rotnakkarin P, Sutcharitchan P, Wannagrairoj P.Prognostic significance of the immunophenotype versus the International Prognostic Index in aggressive non-Hodgkin's lymphoma. Clin Lymphoma 2003; 4(1): 52-5.
  8. Alıcı S, Bavbek S, Kaytan E, Başaran M, Eralp Y, Onat H. Aggressive non-Hodgkin’s Lymphoma treated at the Institute of Oncology, Istanbul: treatment, outcome, and prognostic factors. Am J Clin Oncol 2002; 25(5): 502-8.
  9. Kılçıksız S, Payzın B, Çağlar BU, Gökçe T, Yersal Ö, Deniz S. Non-Hodgkin lenfomalı olgularda standart prognostik faktörlerin 50 ve 60 yaş üstü-altı için değerlendirilmesi ve pik yaşı. Türk Onkoloji Dergisi 2006; 21(1): 11-9.Conconi A, Zucca E, Roggero E, Bertoni F, Bernasconi A, Mingrone W, et al. Prognostic models for diffuse large B-cell lymphoma. Hematol Oncol 2000; 18(2): 61-73.
  10. Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G, et al. International Non-Hodgkin’s Lymphoma Prognostic factors Project. A Predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993; 329(14): 987-94.
  11. Reiser M, Josting A, Soltani M, Staib P, Salzberger B, Diehl V, et al. T-ce